News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
432,496 Results
Type
Article (23791)
Company Profile (153)
Press Release (408552)
Section
Business (132312)
Career Advice (1065)
Deals (25607)
Drug Delivery (96)
Drug Development (63529)
Employer Resources (92)
FDA (10585)
Job Trends (9640)
News (235917)
Policy (22184)
Tag
Academia (1141)
Alliances (33363)
Alzheimer's disease (871)
Approvals (10542)
Artificial intelligence (107)
Bankruptcy (237)
Best Places to Work (7284)
Biosimilars (67)
Biotechnology (71)
Breast cancer (80)
Cancer (856)
Cardiovascular disease (81)
Career advice (880)
Cell therapy (171)
Clinical research (51722)
Collaboration (288)
Compensation (90)
COVID-19 (1415)
C-suite (73)
Data (929)
Diabetes (121)
Diagnostics (3301)
Drug pricing (93)
Earnings (53476)
Employer resources (83)
Events (63046)
Executive appointments (235)
FDA (10988)
Funding (229)
Gene therapy (137)
GLP-1 (521)
Government (2506)
Healthcare (9798)
Infectious disease (1477)
Inflammatory bowel disease (84)
Interviews (148)
IPO (11555)
Job creations (2661)
Job search strategy (792)
Layoffs (268)
Legal (4926)
Lung cancer (130)
Manufacturing (148)
Medical device (5804)
Medtech (5808)
Mergers & acquisitions (14154)
Metabolic disorders (381)
Neuroscience (1085)
NextGen Class of 2024 (3288)
Non-profit (1459)
Northern California (1048)
Obesity (233)
Opinion (191)
Patents (97)
People (38034)
Pharmaceutical (78)
Phase I (16260)
Phase II (22585)
Phase III (17191)
Pipeline (415)
Policy (71)
Postmarket research (1798)
Preclinical (6170)
Radiopharmaceuticals (191)
Rare diseases (179)
Real estate (3639)
Regulatory (15684)
Research institute (1148)
Resumes & cover letters (164)
Southern California (937)
Startups (2297)
United States (9442)
Vaccines (278)
Weight loss (197)
Date
Today (88)
Last 7 days (429)
Last 30 days (2733)
Last 365 days (26242)
2024 (24178)
2023 (28765)
2022 (36259)
2021 (37760)
2020 (35567)
2019 (27248)
2018 (20733)
2017 (22368)
2016 (20553)
2015 (24316)
2014 (18539)
2013 (15315)
2012 (16253)
2011 (16838)
2010 (15559)
Location
Africa (495)
Arizona (77)
Asia (31037)
Australia (5850)
California (2329)
Canada (1003)
China (203)
Colorado (107)
Connecticut (115)
Europe (61520)
Florida (345)
Illinois (207)
Indiana (145)
Maryland (348)
Massachusetts (1882)
Minnesota (130)
New Jersey (795)
New York (710)
North Carolina (502)
Northern California (1048)
Ohio (86)
Pennsylvania (616)
South America (739)
Southern California (937)
Texas (347)
Washington State (294)
432,496 Results for "natco pharma limited".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Natco Pharma Limited Completes Transition of DASH Pharmaceuticals into Natco Pharma USA, Furthering Strategic Presence in the United States
Natco Pharma Limited, a research and development -focused pharmaceutical company based in India, announced that DASH Pharmaceuticals, a company that markets, sells, and distributes generic pharmaceutical products, has officially transitioned to Natco Pharma USA, the U.S. subsidiary of Natco Pharma.
January 2, 2024
·
3 min read
Piramal Pharma Limited Announces Results for Q4 and FY2024
Piramal Pharma Limited, a leading global pharmaceuticals company, announced its standalone and consolidated results for the Fourth Quarter and Full Year ended 31st March 2024.
May 10, 2024
·
8 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Rare diseases
Facing a Dearth of Big Pharma Interest, Rare Disease Players Get Creative to Fund R&D
A handful of billion-dollar deals in the rare disease space highlights the uptick in Big Pharma’s investment, but it’s still extremely low compared to the money flowing to more common indications.
November 20, 2024
·
7 min read
·
Heather McKenzie
MASH
Boston Pharma Carves Out Monthly Treatment Niche in MASH With Strong Phase II Data
Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.
November 18, 2024
·
2 min read
·
Tristan Manalac
Business
Teva and Natco Announce Launch of additional strengths for the Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Teva Pharmaceuticals and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid® 1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States.
March 9, 2023
·
15 min read
Opinion
Opinion: A Small Pharma Mindset Can Reshape Big Pharma and Improve Patient Care
An appreciation for practicality, independent thinking and patient care can help disrupt the bureaucracy of Big Pharma.
September 12, 2024
·
3 min read
·
Jill Marie Drury
Biotech Beach
MEI Pharma Adopts Limited-Duration Stockholder Rights Plan
MEI Pharma, Inc. announced that its Board of Directors has unanimously approved the adoption of a limited-duration stockholder rights plan under which stockholders will receive rights to purchase a new series of preferred stock in certain circumstances.
October 2, 2023
·
9 min read
Drug pricing
Amgen, Lilly Are Part of Ongoing Senate Probe Into Pharma’s Restrictions on 340B Program
A senior senator has asked the CEOs of both companies to provide information about the limits they are putting on 340B drug pricing for hospitals.
September 24, 2024
·
2 min read
·
Tristan Manalac
Piramal Pharma Limited Announces Consolidated Results for Q3 and 9M FY2024
Piramal Pharma Limited announced its standalone and consolidated results for the Third Quarter and Nine Months ended 31st December 2023.
January 30, 2024
·
7 min read
1 of 43,250
Next
